Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background and Aim</h3><p>Lean nonalcoholic fatty liver disease (NAFLD) is a potentially metabolically unhealthy state that refers to NAFLD occurring in non‐overweight/non‐obese subjects. Yet its global epidemiology and metabolic characteristics are not extensively elucidated.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>PubMed, EMBASE, Web of Science and Cochrane databases were searched for eligible studies to January 2020. Random‐effects/fixed‐effects models were used to estimate the global prevalence of lean NAFLD and to compare clinical characteristics among lean non‐NAFLD, lean NAFLD and overwight/obese NAFLD subjects. 'Lean' NAFLD was defined by ethnic‐specific body mass index measurements in the normal range. Meta‐regression and subgroup analyses were performed to determine potential sources of heterogeneity.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>33 observational studies were included with 205,307 individuals from 14 countries. The global prevalence of lean NAFLD was 4.1% (95%CI: 3.4‐4.8%). In lean subjects the prevalence of NAFLD was 9.7% (95%CI: 7.7‐11.8%). The prevalence of lean NAFLD with diabetes, hypertension, metabolic syndrome, dyslipidemia or central obesity was 0.6% (95%CI: 0.4‐0.9%), 1.8% (95%CI: 1.2‐2.5%), 1.4% (95%CI: 1.0‐1.9%), 2.8% (95%CI: 1.9‐3.7%) and 2.0% (95%CI: 1.6‐2.4%), respectively. The prevalence of lean NAFLD showed an upward trend between 1988 and 2017. Asian individuals had the highest prevalence of lean NAFLD (4.8%, 95%CI: 4.0‐5.6%). Middle‐aged people (45‐59 years old) had the highest prevalence of lean NAFLD (4.4%, 95%CI: 3.2‐5.5%). The prevalence of metabolic complications in lean non‐NAFLD, lean NAFLD and overweight/obese NAFLD groups increased sequentially.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>Lean NAFLD occurs with metabolic complications and is not an uncommon condition. The highest prevalence of lean NAFLD occurs in middle‐aged individuals of Asian countries.</p></section>

Global epidemiology of type 2 diabetes in patients with NAFLD or MAFLD: a systematic review and meta-analysis

Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis

The Global Epidemiology Of Non-Alcoholic Fatty Liver Disease And Non-Alcoholic Steatohepatitis Among Patients With Type 2 Diabetes

2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis

Association of Nonalcoholic Fatty Liver Disease with Type 2 Diabetes: Clinical Features and Independent Risk Factors in Diabetic Fatty Liver Patients.

Metabolic (Dysfunction)-Associated Fatty Liver Disease in Chinese Patients with Type 2 Diabetes from a Subcenter of the National Metabolic Management Center

Non-obese non-alcoholic fatty liver disease is correlated with type 2 diabetes in Chinese adults

Cardiovascular and Renal Burdens among Patients with MAFLD and NAFLD in China.

Metabolic characteristics of non-obese and obese metabolic dysfunction-associated fatty liver disease in type 2 diabetes mellitus and its association with diabetic peripheral neuropathy and diabetic retinopathy

Non‐alcoholic fatty liver disease and type 2 diabetes: An update

Associations between metabolic dysfunction-associated fatty liver disease and atherosclerotic cardiovascular disease

Global epidemiology of lean non‐alcoholic fatty liver disease: A systematic review and meta‐analysis

[Study on Prevalence and Risk Factors of Fatty Liver of Patients with Type 2 Diabetes].

MAFLD Vs. NAFLD: Shared Features and Potential Changes in Epidemiology, Pathophysiology, Diagnosis, and Pharmacotherapy

Epidemiology of NAFLD - Focus on diabetes

Prevalence and characteristics of MAFLD in Chinese adults aged 40 years or older: A community-based study

Review article: the epidemiologic burden of non‐alcoholic fatty liver disease across the world

Association of MAFLD With Diabetes, Chronic Kidney Disease, and Cardiovascular Disease: A 4.6-Year Cohort Study in China

Nonalcoholic Fatty Liver Disease and Associated Metabolic Risks of Hypertension in Type 2 Diabetes: A Cross-Sectional Community-Based Study.

Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: A Bidirectional Relationship

Clinical Feathers of Nonalcoholic Fatty Liver Disease in middle-aged Patients with Type 2 Diabetes Mellitus